(Q34044322)

30 July 2017

title

The effect of bevacizumab on corneal neovascularization in rabbits (English)

1 reference

corneal neovascularization

30 July 2017

1 reference

1 reference

1 reference

Wung-Jae Kim

1

1 reference

30 July 2017

Hee-Ok Jeong

series ordinal

2

1 reference

30 July 2017

Sung-Kun Chung

series ordinal

3

1 reference

30 July 2017

publication date

3 August 2010

1 reference

Korean Journal of Ophthalmology

30 July 2017

published in

1 reference

30 July 2017

volume

24

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

230-236

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

30 July 2017

copyright license

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Safety profile of bevacizumab on cultured human corneal cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Pegaptanib in the treatment of wet, age-related macular degeneration

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Photodynamic therapy for corneal neovascularization.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Laser photocoagulation of feeder vessels in lipid keratopathy.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Inhibitory effect of triamcinolone acetonide on corneal neovascularization

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Suppression of corneal neovascularization by PEDF release from human amniotic membranes

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Corneal neovascularization

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916105

Subconjunctival bevacizumab for corneal neovascularization

28 October 2018

1 reference

12 December 2020

Topical application of methotrexate for inhibition of corneal angiogenesis

1 reference

12 December 2020

Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells

1 reference

12 December 2020

Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas

1 reference

12 December 2020

Angiostatin inhibits and regresses corneal neovascularization

1 reference

12 December 2020

Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization

1 reference

12 December 2020

Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea

1 reference

12 December 2020

Loss and restoration of immune privilege in eyes with corneal neovascularization

1 reference

12 December 2020

Ocular Neovascularization

1 reference

12 December 2020

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

1 reference

12 December 2020

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration

1 reference

12 December 2020

Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis

1 reference

12 December 2020

Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma

1 reference

12 December 2020

10.3341/KJO.2010.24.4.230

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference